Artificial Intelligence company BenevolentAI has bought a drug discovery and development facility at the Babraham Research Campus in Cambridge for an undisclosed sum.
Last month the biotech Axovant was rocked by the failure of its star drug intepirdine in Alzheimer’s disease – and the fall-out is still being felt, with CEO David Hung deciding to walk out.
